Alnylam Faces Near-Term Risk on Amvuttra, Oppenheimer Says

01:11 PM EDT, 10/30/2026 (MT Newswires) -- Alnylam Pharmaceuticals (ALNY) faces near-term risk with Amvuttra on potential changes to 2027 340B reimbursement plan, Oppenheimer said in a note Thursday. "Next week, we look for publication of final 340B changes slated to take effect 1/1/2027," the report said. "A final discount rate less than the proposed 33.4% could drive 10-20%+ upside." The note said the market priced in the worst-case scenario for Amvuttra's outlook. The drug is used to treat adult amyloidosis. "ALNY price assumes -9% CAGR for Amvuttra in 2027-2035, and renders ALNY...a takeout candidate," the note said, pointing to Sanofi (SNY) as the most reasonable acquirer. Oppenheimer kept its buy rating while lowering its price target to $320 from $350. Price: 171.64, Change: -2.37, Percent Change: -1.36